StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)
November 5, 2024 4:19 PM
Chardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Oppenheimer Reiterates Perform Rating on Editas Medicine (EDIT)
November 5, 2024 12:43 PM
Editas Medicine (EDIT) PT Lowered to $11 at Stifel
November 5, 2024 7:50 AM
Editas Medicine (EDIT) PT Lowered to $7 at Wells Fargo
November 5, 2024 6:29 AM
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
November 5, 2024 5:23 AM
Editas Medicine (EDIT) PT Lowered to $5 at RBC Capital
November 4, 2024 3:25 PM
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities
November 4, 2024 12:25 PM
Raymond James Downgrades Editas Medicine (EDIT) to Market Perform
November 4, 2024 12:23 PM
Form SC 13G/A Editas Medicine, Inc. Filed by: VANGUARD GROUP INC
November 4, 2024 11:57 AM
Editas Medicine (EDIT) Reports In-Line Q3 EPS
November 4, 2024 7:45 AM
Form 10-Q Editas Medicine, Inc. For: Sep 30
November 4, 2024 7:37 AM
Form 8-K Editas Medicine, Inc. For: Nov 04
November 4, 2024 7:34 AM
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
November 4, 2024 7:30 AM
